<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00265473</url>
  </required_header>
  <id_info>
    <org_study_id>0407M62505</org_study_id>
    <nct_id>NCT00265473</nct_id>
  </id_info>
  <brief_title>MGA031, Sirolimus and Tacrolimus in Islet Transplantation</brief_title>
  <official_title>hOKT3γ1 (Ala-Ala), Sirolimus and Low Dose Tacrolimus Therapy in Type 1 Diabetic Islet Allograft Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is designed to extend the observations made in our pilot clinical trial&#xD;
      (IND 8971, Study #1) on the safety and efficacy of immunotherapy with the anti-CD3 monoclonal&#xD;
      antibody hOKT3γ1 (Ala-Ala), (currently called MGA031) combined with sirolimus and tacrolimus&#xD;
      in preventing rejection and autoimmune destruction of deceased donor pancreatic islet&#xD;
      transplants in type 1 diabetic recipients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 1 diabetes mellitus continues to be a therapeutic challenge. Previous studies have shown&#xD;
      that failure to prevent hypoglycemia and hyperglycemia results in acute and chronic&#xD;
      complications, leading to poor quality of life, premature death, and considerable health care&#xD;
      costs in 30% to 50% of diabetic patients. Therefore, establishing safe and effective ways to&#xD;
      achieve and maintain normoglycemia would have substantial implications for the well-being of&#xD;
      individuals with diabetes. Intensive insulin therapy has been shown to reduce the risk of&#xD;
      chronic complications in patients who achieve near-normalization of glycemia. However, such&#xD;
      therapy is labor-intensive, difficult to implement for many patients, and limited by the&#xD;
      accompanying increased frequency of severe hypoglycemia. Currently, the only way to restore&#xD;
      and sustain normoglycemia without the associated risk of hypoglycemia is by replacing the&#xD;
      patient's islets of Langerhans, either by transplanting a vascularized pancreas or, much less&#xD;
      invasively, by infusing isolated islets.&#xD;
&#xD;
      Strategies that selectively inactivate autoreactive T cells and prevent allorejection of&#xD;
      transplanted islets in the absence of diabetogenic side effects need to be developed for&#xD;
      islet transplants to survive in autoimmune diabetic recipients. The current clinical study&#xD;
      will extend the observations made in our first pilot clinical trial (IND 8971, Study #1) that&#xD;
      provided preliminary information on the safety and efficacy of immunotherapy with the&#xD;
      anti-CD3 monoclonal antibody hOKT3γ1 (Ala-Ala), (currently called MGA031) combined with&#xD;
      sirolimus and tacrolimus in preventing rejection and autoimmune destruction of deceased donor&#xD;
      pancreatic islet transplants in type 1 diabetic recipients.&#xD;
&#xD;
      In the pilot study 4 of 6 single islet transplant recipients remained insulin independent&#xD;
      with normal HbA1c and no episodes of hypoglycemia throughout the 1 year post-transplant&#xD;
      period. Three of those four participants have maintained insulin independence for &gt; 3.5, &gt;4.5&#xD;
      and &gt;5 years post islet transplant. These preliminary findings warrant an extension study&#xD;
      involving more recipients and more comprehensive immunologic monitoring to examine in greater&#xD;
      detail the impact of MGA031 induction immunotherapy on T cell responses operative in&#xD;
      rejection and autoimmune destruction of transplanted islets as well as on formation of&#xD;
      regulatory T cell function for the protection of transplanted islets.&#xD;
&#xD;
      A total of 5 patients with type 1 diabetes will be transplanted under this protocol. Islet&#xD;
      transplant recipients will be admitted for 5 days and followed for one year after&#xD;
      transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects With Full Islet Function.</measure>
    <time_frame>At one year after initial transplant.</time_frame>
    <description>Proportion of subjects with full islet function (i.e. insulin independent) at one year after initial islet transplant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Events Related to Immunosuppressive Therapy.</measure>
    <time_frame>Day 0 - Day 365</time_frame>
    <description>Number of serious adverse events related to immunosuppressive therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects With Partial Islet Function and no Episodes of Severe Hypoglycemia;</measure>
    <time_frame>At one year after initial transplant</time_frame>
    <description>Proportion of subjects with partial islet function and no episodes of severe hypoglycemia at one year after initial islet transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Independent Single-donor Subjects.</measure>
    <time_frame>At 75 days after transplant</time_frame>
    <description>Proportion of insulin independent single-donor subjects at day 75 after transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Independent Multiple-donor Subjects.</measure>
    <time_frame>At one year after final transplant</time_frame>
    <description>Proportion of insulin independent multiple-donor subjects at one year after final transplant. Participant received more than one islet transplant.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>Allogeneic Islets of Langerhans</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Islet infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic Islets of Langerhans</intervention_name>
    <description>Intraportal infusion of islets of Langerhans</description>
    <arm_group_label>Allogeneic Islets of Langerhans</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 to 65 years of age.&#xD;
&#xD;
          2. Ability to provide written informed consent.&#xD;
&#xD;
          3. Mentally stable and able to comply with the procedures of the study.&#xD;
&#xD;
          4. Clinical history compatible with type 1 diabetes with onset of disease at &lt;40 years of&#xD;
             age and insulin-dependence for &gt; 5 years at the time of enrollment.&#xD;
&#xD;
          5. Absent stimulated C-peptide (&lt;0.3ng/ml) in response to a mixed meal tolerance test.&#xD;
&#xD;
          6. Involvement in intensive diabetes management defined as self monitoring of glucose&#xD;
             values no less than a mean of three times each day averaged over each week and by the&#xD;
             administration of three or more insulin injections each day or insulin pump therapy.&#xD;
             Such management must be under the direction of an endocrinologist, diabetologist, or&#xD;
             diabetes specialist with at least 3 clinical evaluations during the previous 12&#xD;
             months.&#xD;
&#xD;
          7. At least one episode of severe hypoglycemia in the past 3 years defined as an event&#xD;
             with symptoms compatible with hypoglycemia in which the subject required the&#xD;
             assistance of another person and which was associated with either a blood glucose&#xD;
             level &lt; 50 mg/dl or prompt recovery after oral carbohydrate, intravenous glucose, or&#xD;
             glucagon administration).&#xD;
&#xD;
          8. Reduced awareness of hypoglycemia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any previous transplant.&#xD;
&#xD;
          2. BMI &gt;27 kg/m2 or patient weight ≤ 50kg.&#xD;
&#xD;
          3. Insulin requirement of &gt; 0.8 IU/kg/day or 50 IU/day.&#xD;
&#xD;
          4. HbA1c &gt;10%.&#xD;
&#xD;
          5. Untreated proliferative diabetic retinopathy.&#xD;
&#xD;
          6. Uncontrolled Hypertension.&#xD;
&#xD;
          7. Estimated glomerular filtration rate &lt;70 ml/min/1.73 m2 for females and &lt;80&#xD;
             ml/min/1.73 m2 for males&#xD;
&#xD;
          8. Presence or history of macroalbuminuria (&gt;300mg/d).&#xD;
&#xD;
          9. Presence or history of panel-reactive anti-HLA antibodies &gt;20% by flow cytometry.&#xD;
&#xD;
         10. Females: Positive pregnancy test, presently breast-feeding, or unwillingness to use&#xD;
             effective contraceptive measures for the duration of the study and 3 months after&#xD;
             discontinuation. Males: intent to procreate during the duration of the study or within&#xD;
             3 months after discontinuation or unwillingness to use effective measures of&#xD;
             contraception.&#xD;
&#xD;
         11. Active infection.&#xD;
&#xD;
         12. Negative screen for Epstein-Barr Virus (EBV).&#xD;
&#xD;
         13. Invasive aspergillus infection within one year prior to study entry.&#xD;
&#xD;
         14. Any history of malignancy except for completely resected squamous or basal cell&#xD;
             carcinoma of the skin.&#xD;
&#xD;
         15. Active alcohol, tobacco or substance abuse.&#xD;
&#xD;
         16. Baseline Hgb below the lower limits of normal at the local laboratory; lymphopenia,&#xD;
             neutropenia, or thrombocytopenia.&#xD;
&#xD;
         17. A history of Factor V deficiency.&#xD;
&#xD;
         18. Any coagulopathy or medical condition requiring long-term anticoagulant therapy.&#xD;
&#xD;
         19. Severe co-existing cardiac disease.&#xD;
&#xD;
         20. Persistent elevation of liver function tests.&#xD;
&#xD;
         21. Symptomatic cholecystolithiasis.&#xD;
&#xD;
         22. Acute or chronic pancreatitis.&#xD;
&#xD;
         23. Symptomatic peptic ulcer disease.&#xD;
&#xD;
         24. Unremitting diarrhea, vomiting or other gastrointestinal disorders potentially&#xD;
             interfering with absorption.&#xD;
&#xD;
         25. Hyperlipidemia despite medical therapy (fasting LDL cholesterol &gt; 130 mg/dl, treated&#xD;
             or untreated; and/or fasting triglycerides &gt; 200 mg/dl).&#xD;
&#xD;
         26. Chronic use of systemic steroids.&#xD;
&#xD;
         27. Use of any other investigational agents within 4 weeks of participation.&#xD;
&#xD;
         28. Administration of live attenuated vaccine(s) within 2 months of enrollment.&#xD;
&#xD;
         29. Any medical condition that, in the opinion of the investigator, will interfere with&#xD;
             the safe completion of the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernhard J. Hering, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.surg.umn.edu/diabinst/home.html</url>
    <description>U of MN Diabetes Institute for Immunology and Transplantation</description>
  </link>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>December 12, 2005</study_first_submitted>
  <study_first_submitted_qc>December 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2005</study_first_posted>
  <results_first_submitted>April 1, 2011</results_first_submitted>
  <results_first_submitted_qc>August 16, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 21, 2011</results_first_posted>
  <last_update_submitted>January 26, 2017</last_update_submitted>
  <last_update_submitted_qc>January 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Experimental</title>
          <description>Islet infusion with MGA031 induction and sirolimus and tacrolimus maintenance immunosuppression.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental</title>
          <description>Islet infusion with MGA031 induction and sirolimus and tacrolimus maintenance immunosuppression.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.4" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjects With Full Islet Function.</title>
        <description>Proportion of subjects with full islet function (i.e. insulin independent) at one year after initial islet transplant.</description>
        <time_frame>At one year after initial transplant.</time_frame>
        <population>The number of participants was based on the participants that were actually transplanted.</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Islet infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Full Islet Function.</title>
          <description>Proportion of subjects with full islet function (i.e. insulin independent) at one year after initial islet transplant.</description>
          <population>The number of participants was based on the participants that were actually transplanted.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serious Adverse Events Related to Immunosuppressive Therapy.</title>
        <description>Number of serious adverse events related to immunosuppressive therapy.</description>
        <time_frame>Day 0 - Day 365</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Islet infusion with MGA031 induction and sirolimus and tacrolimus maintenance immunosuppression.</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events Related to Immunosuppressive Therapy.</title>
          <description>Number of serious adverse events related to immunosuppressive therapy.</description>
          <units>Serious Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Partial Islet Function and no Episodes of Severe Hypoglycemia;</title>
        <description>Proportion of subjects with partial islet function and no episodes of severe hypoglycemia at one year after initial islet transplant.</description>
        <time_frame>At one year after initial transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Islet infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Partial Islet Function and no Episodes of Severe Hypoglycemia;</title>
          <description>Proportion of subjects with partial islet function and no episodes of severe hypoglycemia at one year after initial islet transplant.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Independent Single-donor Subjects.</title>
        <description>Proportion of insulin independent single-donor subjects at day 75 after transplant</description>
        <time_frame>At 75 days after transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Islet infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Independent Single-donor Subjects.</title>
          <description>Proportion of insulin independent single-donor subjects at day 75 after transplant</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Independent Multiple-donor Subjects.</title>
        <description>Proportion of insulin independent multiple-donor subjects at one year after final transplant. Participant received more than one islet transplant.</description>
        <time_frame>At one year after final transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Islet infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Independent Multiple-donor Subjects.</title>
          <description>Proportion of insulin independent multiple-donor subjects at one year after final transplant. Participant received more than one islet transplant.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Experimental</title>
          <description>Islet infusion with MGA031 induction and sirolimus and tacrolimus maintenance immunosuppression.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Melena D. Bellin, MD</name_or_title>
      <organization>Schulze Diabetes Institute, University of Minnesota</organization>
      <phone>612-625-4686</phone>
      <email>bell0130@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

